NOT-CA-20-003: Notice of Correction to RFA-CA-19-052, "Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)"

Notice of Correction to RFA-CA-19-052, "Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)"

Notice Number: NOT-CA-20-003

Key Dates
Release Date: October 22, 2019

Related Announcements
RFA-CA-19-052

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants about a correction to the Application and Submission Information section in RFA-CA-19-052, "Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)".

The correction applies to Section IV. Application and Submission Information, 2. Content and Form of Application Submission, subheading PHS 398 Research Plan (Overall)

Currently reads:

Research Strategy: Research Strategy for Overall should be structured in sub-sections as defined below (instead of standard subsections defined in SF424 Application Guidelines).

Should correctly read (in italics)

Research Strategy: Research Strategy for Overall should be structured as defined in SF424 Application Guidelines.

All other aspects of RFA-CA-19-052 remain unchanged.

Inquiries

Please direct all inquiries to:

Laurence (Austin) Doyle, MD
National Cancer Institute (NCI)
Telephone: 240-276-6112
Email: [email protected]

Jeffrey Hildesheim, PhD
National Cancer Institute (NCI)
Telephone: 240-276-6230
Email: [email protected]